Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold ...

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim ...

Buy AbbVie (ABBV) stock? See more on its 2025 EPS growth outlook from Skyrizi/Rinvoq, valuation at 14.4x FY27, key risks, and ...

From a valuation standpoint, AbbVie is at a premium to the industry. Based on the price/earnings (P/E) ratio, the company’s ...

AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

AbbVie Inc. (NYSE:ABBV – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Thursday after Berenberg Bank upgraded the stock from a hold rating to a buy rating. Berenberg ...

In the current session, the stock is trading at $233.57, after a 0.52% spike. Over the past month, AbbVie Inc. (NYSE:ABBV) stock increased by 0.94%, and in the past year, by 40.22%. With performance ...